Challenges
Arboviral infections pose a growing global clinical and public health burden, with particularly high prevalence in tropical and subtropical regions and rising cross-border transmission risks amid increasing international travel. For hospital outpatient and emergency departments, border quarantine authorities, grassroots clinics and frontline public health agencies, conventional diagnostic approaches for arboviral pathogens have four core unmet needs:
Highly overlapping symptoms with poor differential diagnostic yield
Most arboviral infections — including dengue, Zika, chikungunya and West Nile fever — present with nearly identical early symptoms such as acute fever, rash, myalgia and arthralgia, with frequent mixed infections in co-endemic areas. Conventional single-target assays and rapid antigen tests have limited coverage and low sensitivity, leading to high missed diagnosis rates. The inability to differentiate dengue serotypes also creates barriers to early severe dengue warning and targeted clinical management.
Delayed centralized testing slows clinical intervention and outbreak response
Traditional nucleic acid testing relies on centralized molecular laboratories, with lengthy sample transport and batch processing workflows that take hours to days to deliver results. For time-sensitive conditions such as severe dengue, delayed diagnosis directly worsens patient prognosis. For port quarantine and outbreak scenarios, slow testing also hinders timely infection control implementation and source tracing.
High operational barriers limit deployment in endemic and frontline settings
Conventional molecular diagnostics require standardized PCR laboratories and certified technical personnel. These conditions are often unavailable in high-prevalence tropical regions, grassroots medical facilities, border ports and field outbreak sites, resulting in extremely limited access to reliable arboviral testing.
Inflexible throughput and cold chain reliance restrict grassroots deployment
Daily sample volumes in primary care settings are typically low, leaving high-throughput PCR instruments idle and cost-inefficient, while sudden outbreak surges demand rapid throughput expansion. Additionally, traditional reagents rely strictly on cold chain storage and transportation, creating further barriers to large-scale public health deployment in remote and tropical regions.
Core Benefits
The 8 Arboviral Pathogen Nucleic Acid Detection Kit, paired with the Flex-Disc fully automated nucleic acid analysis platform, directly addresses the above outpatient, primary care and public health pain points:
One-stop 8-plex pathogen profiling for accurate differential diagnosis
A single run covers 8 globally prevalent pathogenic arboviruses, including 4 dengue virus serotypes (DENV-1/2/3/4), Zika virus, chikungunya virus, yellow fever virus and West Nile virus. It accurately identifies single and mixed infections with clear serotype differentiation, eliminating the need for sequential separate testing and greatly improving diagnostic efficiency for acute febrile illness workup.
Results in around 40 minutes to capture critical diagnosis and response windows
Total testing time is around 40 minutes, with only 1 minute of hands-on sample loading — far faster than centralized laboratory workflows. Rapid etiological results support early warning of severe dengue and timely clinical management, while also enabling on-site rapid quarantine at ports of entry to block imported case spread.
Low-barrier POCT deployment to expand decentralized testing access
Powered by the fully automated closed Flex-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be operated by frontline medical workers after brief training. It can be deployed directly in infectious disease outpatient departments, grassroots clinics, border quarantine stations and field outbreak sites, with on-demand testing for samples as they arrive, significantly shortening diagnostic turnaround time.
Modular scalable throughput to adapt to diverse scenario needs
Each independent Flex-Disc testing module processes one sample at a time, with a single control terminal supporting wireless connection to up to 8 modules simultaneously. Facilities can scale the number of modules according to actual sample volume: a single module meets routine primary care and outpatient demand, while multi-module parallel operation handles outbreak surges and mass public health screening, balancing operational cost and testing capacity.
Core Product Advantages
Dual-purpose 8-plex panel design for clinical and public health scenarios
The panel covers 8 WHO-prioritized pathogenic arboviruses, including all 4 dengue serotypes, and is fully suited for acute febrile illness differential diagnosis, travel medicine, entry-exit port quarantine and outbreak emergency screening, meeting the needs of both hospital outpatient departments and public health agencies.
Fully automated closed sample-to-result workflow
Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true load-and-go detection.
Modular scalable throughput design for flexible deployment
Compatible with the Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer, each testing module processes 1 sample per run with full results available in around 40 minutes. One main control terminal can connect wirelessly to up to 8 testing modules, supporting random access and parallel testing to flexibly match sample volumes from small grassroots clinics to hospital outpatient and public health screening sites.

Lyophilized reagents for room-temperature storage and transport
With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance. This greatly reduces storage and logistics costs for tropical endemic regions, remote grassroots sites and field testing scenarios.
Zero cross-contamination closed cartridge system
Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control requirements, and ensures stable, reliable results even in non-laboratory field settings.
CE-compliant with validated clinical sample compatibility
The assay is fully validated for human serum and EDTA-anticoagulated plasma samples. All 8 targets are CE-marked, meeting regulatory requirements for clinical diagnosis, public health surveillance and border quarantine across global primary care and outpatient markets.